Labgenomics Co

Labgenomics Co EPS

The Earnings per Share (EPS) of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -7,092.28 KRW. In the previous year, Earnings per Share (EPS) was -2,621.66 KRW — a change of 170.53% (lower).

EPS

-7,092.28KRW

YoY

170.53%

Last updated:

Earnings per Share (EPS) of Labgenomics Co is 2025 -7,092.28 KRW. Earnings per Share (EPS) of Labgenomics Co was 2024 -2,621.66 KRW. It decreases by 170.53% lower compared to the previous year.

The Labgenomics Co EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
106.03 KRW
Jan 1, 2020
4,711.67 KRW
Jan 1, 2021
9,238.49 KRW
Jan 1, 2022
5,332.03 KRW
Jan 1, 2023
-514.94 KRW
Jan 1, 2024
-2,621.66 KRW
Jan 1, 2025
-7,092.28 KRW
Jan 1, 2026 (e)
476.72 KRW
The Labgenomics Co EPS history
YEAREPSYoY
est476.72KRW-106.72%
-7,092.28KRW+170.53%
-2,621.66KRW+409.12%
-514.94KRW-109.66%
5,332.03KRW-42.28%
9,238.49KRW+96.08%
4,711.67KRW+4,343.63%
106.03KRW-124.23%
-437.70KRW+8.48%
-403.48KRW-606.18%
79.71KRW-55.51%
179.18KRW-32.80%
266.63KRW+48.13%
180.00KRW+31.39%
137.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Earnings per Share (EPS) of Labgenomics Co is -7,092.28 KRW in 2025.

Earnings per Share (EPS) of Labgenomics Co changed from -2,621.66 KRW to -7,092.28 KRW, representing a 170.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Labgenomics Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Labgenomics Co